Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects
Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia
Melbourne Dental School, University of Melbourne, Melbourne, VIC 3000, Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3000, Australia
Centre of Excellence for Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia
Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC 3000, Australia
Author to whom correspondence should be addressed.
Academic Editor: Sikander Ailawadhi
Received: 8 August 2021
Revised: 29 August 2021
Accepted: 2 September 2021
Published: 6 September 2021
Myeloma is a common cancer involving the bone marrow. Some of the medications used in the treatment of myeloma, including those that reduce the risk of bone fractures, can increase the chance of side effects occurring in the jawbone. The most serious complication in the jawbone is called medication-related osteonecrosis, meaning part of the jawbone dies. The aim of this review is to highlight some of the medications that are implicated and other risk factors that can contribute to osteonecrosis. Suggestions to prevent this complication from occurring are described. Conventional methods of treating established medication-related osteonecrosis of the jawbone are outlined as well as emerging new treatments.